In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.
第二部分对视神经脊髓炎,多发性硬化以人的血清进行NMO-IgG测定,判断NMO-IgG是否能作鉴别视神经脊髓炎,多发性硬化的验室依据。